Coping with the onslaught of industry initiatives. What's best for investigative sites?

Sites are dynamic environments, and new technology and industry initiatives are an important complement to the critical need for relationship building and maintenance. But are they helping improve site and sponsor-CRO collaboration, and creating a competitive edge through improved clinical trial performance?

To explore these issues and their impact, the Society for Clinical Research Sites (SCRS) and Oracle Health Sciences surveyed clinical professionals involved in clinical research at investigative sites around the world.

The study comprises data from 505 qualified respondents, 97% of which are actively participating in clinical trials, representing a significant voice of the market. Respondents were from around the globe with 85% from North America and 15% from the rest of the world.

Areas examined in the research include:

  • Study engagement trends associated with site type and location
  • Impact of a consolidated investigator platform on investigative sites
  • Impact of site networks on investigative sites
  • Impact of technology (both current and future) on the investigative site and their ability to conduct a clinical trial
  • Impact of Decentralized Clinical Trials (DCTs) on investigative sites
  • Technology trends and perceptions with regards to a ACRP/CenterWatch 2016 study
Read Research Report
Image

Sites are overwhelmed with too many solutions and ballooning login credentials. Instead of engaging with patients, an inordinate amount of time is spent learning new systems, completing redundant required training and reentering the same data multiple times. Simultaneously, pharmaceutical companies and CROs are left with a fragmented ecosystem of software, hardware, vendors, and processes that ultimately distracts everyone involved from the goals of clinical research.

-Jim Kremidas, Executive Director, Association of Clinical Research Professionals

Oracle for Health Sciences.